English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/37163
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorMarín, Concepció-
dc.contributor.authorAguilar, Esther-
dc.contributor.authorMengod Los Arcos, Guadalupe-
dc.contributor.authorCortés, Roser-
dc.contributor.authorRodríguez-Oroz, M. Cruz-
dc.contributor.authorObeso, José Ángel-
dc.date.accessioned2011-06-27T08:02:53Z-
dc.date.available2011-06-27T08:02:53Z-
dc.date.issued2008-12-
dc.identifier.citationNeurobiology of Diseasees_ES
dc.identifier.issn0969-9961-
dc.identifier.urihttp://hdl.handle.net/10261/37163-
dc.descriptionEl pdf del artículo es el manuscrito de autor.es_ES
dc.description.abstractCoadministration of entacapone with levodopa attenuates motor complications in experimental models of Parkinson's disease. The mechanisms underlying entacapone effects are unknown. We investigated the effect of entacapone, on: long-duration response (LDR) to levodopa, levodopa-induced postsynaptic pharmacodynamic mechanisms and molecular changes in hemiparkinsonian rats. 6-Hydroxydopamine-unilaterally lesioned rats were treated with levodopa (25 mg/kg) + vehicle; levodopa + entacapone (30 mg/kg) or saline, twice daily for 22 days. The LDR and the apomorphine-induced rotations were measured. In situ hybridization was performed measuring the expression of striatal preproenkephalin, preprodynorphin and dopamine D-3 receptor mRNAs, subthalamic cytochrome oxidase mRNA and nigral glutamic acid decarboxylase mRNA. Entacapone potentiated the LDR but did not modify either the apomorphine-induced rotational behavior or the molecular changes. Our results suggest that the effects of entacapone on levodopa-induced motor response are not mediated by postsynaptic mechanisms and that administration of entacapone is not able to normalize the molecular alterations induced by levodopa in the basal ganglia.es_ES
dc.description.sponsorshipThis work was supported by an unrestricted grant from Novartis-Orion Pharma (Barcelona, Spain). JAO serves as external adviser for Novartis Pharmaceutical (Barcelona, Spain). EA is partially financed by the program: Ayudas para Contratos de Apoyo a la Investigación en el Sistema Nacional de Salud from the Ministerio de Sanidad y Consumo of the Spanish Government.-
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsopenAccesses_ES
dc.subjectParkinson's diseasees_ES
dc.subjectLevodopaes_ES
dc.subjectEntacaponees_ES
dc.subject6-Hydroxydopaminees_ES
dc.subjectPreproenkephalines_ES
dc.subjectPreprodynorphines_ES
dc.titleEntacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changeses_ES
dc.typeartículoes_ES
dc.identifier.doi10.1016/j.nbd.2008.07.019-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.nbd.2008.07.019es_ES
dc.identifier.e-issn1095-953X-
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
Entacapone potentiates.pdf627,14 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.